CYTOTOXICITY OF A NOVEL ANTI-ICAM-1 IMMUNOTOXIN ON HUMAN MYELOMA CELL-LINES

被引:16
作者
HUANG, YW
BURROWS, FJ
VITETTA, ES
机构
[1] UNIV TEXAS, SW MED CTR, CTR CANC IMMUNOBIOL, 6000 HARRY HINES BLVD, DALLAS, TX 75235 USA
[2] UNIV TEXAS, SW MED CTR, DEPT MICROBIOL, DALLAS, TX 75235 USA
来源
HYBRIDOMA | 1993年 / 12卷 / 06期
关键词
D O I
10.1089/hyb.1993.12.661
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
We have generated a murine monoclonal antibody (UV3) which recognizes an epitope on ICAM-1 expressed on myeloma cells. By flow cytometric analysis, the epitope on ICAM-1 recognized by this antibody is strongly expressed on human myeloma cells, pre-B leukemia cells and Burkitt's lymphoma cell lines. Most human T cell lines are weakly positive. The antibody does not react with red blood cells, polymorphonuclear leukocytes (PMNs) or resting B lymphocytes from normal donors, and reacts very weakly with resting T cells. Immunohistochemical assays indicate that the antibody does not react with normal liver, kidney, heart, brain, thymus or lung. An immunotoxin (IT) was prepared by coupling UV3 to deglycosylated ricin A-chain (dgA). In protein synthesis inhibition assays it was highly cytotoxic to the human myeloma cell lines HS-SULTAN (IC50 = 1 X 10(-11)M) and ARH-77 (IC50 = 9 X 10(-11)M), but not to cell lines of T cell lineage or most cell lines of the B lineage. Our results suggest that the UV3-dgA may have therapeutic potential for the treatment of human multiple myeloma.
引用
收藏
页码:661 / 675
页数:15
相关论文
共 42 条
  • [1] AEKIN S, 1991, BLOOD, V77, P948
  • [2] AHSMANN EJM, 1992, BLOOD, V79, P2068
  • [3] BARKEEEER HF, 1993, BLOOD, V80, pA360
  • [4] BJORN MJ, 1985, CANCER RES, V45, P1214
  • [5] BOYD AW, 1989, BLOOD, V73, P1896
  • [6] BREGNI M, 1989, BLOOD, V73, P753
  • [7] BURROWS FJ, 1991, CANCER RES, V51, P4768
  • [8] CALIGARISCAPPIO F, 1991, BLOOD, V77, P2688
  • [9] DRACH J, 1991, CLIN EXP IMMUNOL, V83, P418
  • [10] GHETIE MA, 1988, CANCER RES, V48, P2610